HUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal
HUTCHMED stock soared on Thursday after the company announced a new licensing deal with GlaxoSmithKline.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 130,200 | $1,400,952 | -2% | 0% |
| 2. | Citadel Investment Group Ken Griffin | 38,061 | $409,536 | +25% | 0% |
| 3. | Millennium Management Israel Englander | 26,420 | $284,279 | -6% | 0% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,477,494 | $15,823,961 | 0.01% | |
| 2. | 674,511 | $7,257,739 | 0.01% | |
| 3. | 313,611 | $3,374,454 | 0% | |
| 4. | 291,229 | $3,133,624 | 0.04% | |
| 5. | 242,791 | $2,670,701 | 0.01% |